Stoke Therapeutics reported the completion of patient enrollment in its Phase 3 EMPEROR study for zorevunersen, targeting Dravet Syndrome, with data readout expected in Q3 2027 [S2][S27]. The company is engaging the FDA on potential expedited review pathways while preparing a rolling NDA submission beginning in early 2027 [S12][S27]. Stoke currently holds approximately $110 million in cash with a strong current ratio of 7.69, reflecting solid financial resources to fund operations through anticipated data milestones [F1]. As a clinical-stage biotech focused on rare genetic diseases, Stoke's operating model depends heavily on successful late-stage clinical outcomes and collaborations to sustain long development cycles [S1]. Ongoing risks include trial execution, regulatory approval uncertainties, and capital needs amid development expenses.